FDA wants additional data on Kala Pharma’s KPI-121

There was disappointment for US drug developer Kala Pharmaceuticals (Nasdaq: KALA), as it received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.